Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Shares Acquired by Strs Ohio

Strs Ohio raised its position in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 385.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,100 shares of the company’s stock after acquiring an additional 10,400 shares during the quarter. Strs Ohio’s holdings in Taro Pharmaceutical Industries were worth $547,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp raised its holdings in shares of Taro Pharmaceutical Industries by 1.4% during the third quarter. Bank of New York Mellon Corp now owns 22,223 shares of the company’s stock valued at $838,000 after acquiring an additional 307 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Taro Pharmaceutical Industries by 24.5% in the fourth quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock valued at $195,000 after purchasing an additional 921 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Taro Pharmaceutical Industries in the third quarter valued at approximately $65,000. FNY Investment Advisers LLC acquired a new stake in shares of Taro Pharmaceutical Industries in the fourth quarter valued at approximately $105,000. Finally, Metis Global Partners LLC acquired a new stake in shares of Taro Pharmaceutical Industries in the third quarter valued at approximately $262,000. Institutional investors and hedge funds own 91.40% of the company’s stock.

Taro Pharmaceutical Industries Stock Down 0.2 %

TARO stock opened at $42.40 on Friday. Taro Pharmaceutical Industries Ltd. has a 52-week low of $24.69 and a 52-week high of $45.76. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of 34.75 and a beta of 0.61. The business has a fifty day moving average of $42.14 and a two-hundred day moving average of $40.03.

Taro Pharmaceutical Industries (NYSE:TARO) last released its quarterly earnings results on Thursday, January 25th. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.26. The business had revenue of $157.15 million during the quarter, compared to analysts’ expectations of $154.90 million. Taro Pharmaceutical Industries had a return on equity of 3.26% and a net margin of 7.48%. As a group, sell-side analysts anticipate that Taro Pharmaceutical Industries Ltd. will post 1.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on TARO shares. HC Wainwright cut Taro Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $43.00 price target for the company. in a report on Thursday, January 18th. StockNews.com started coverage on Taro Pharmaceutical Industries in a report on Saturday. They issued a “strong-buy” rating for the company.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.